The added value of an electronic monitoring and alerting system in the management of medication-overuse headache: A controlled multicentre study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
The added value of an electronic monitoring and alerting system in the management of medication-overuse headache : A controlled multicentre study. / Tassorelli, Cristina; Jensen, Rigmor; Allena, Marta; De Icco, Roberto; Katsarava, Zaza; Miguel Lainez, J; Leston, Jorge A; Fadic, Ricardo; Spadafora, Santiago; Pagani, Marco; Nappi, Giuseppe; Comoestas Consortium.
I: Cephalalgia : an international journal of headache, Bind 37, Nr. 12, 2017, s. 1115-1125.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The added value of an electronic monitoring and alerting system in the management of medication-overuse headache
T2 - A controlled multicentre study
AU - Tassorelli, Cristina
AU - Jensen, Rigmor
AU - Allena, Marta
AU - De Icco, Roberto
AU - Katsarava, Zaza
AU - Miguel Lainez, J
AU - Leston, Jorge A
AU - Fadic, Ricardo
AU - Spadafora, Santiago
AU - Pagani, Marco
AU - Nappi, Giuseppe
AU - Comoestas Consortium
PY - 2017
Y1 - 2017
N2 - Background Medication-overuse headache (MOH) is a chronic disabling condition associated with a high rate of relapse. Methods We evaluated whether the adoption of electronic-assisted monitoring, advice and communication would improve the outcome over a follow-up of 6 months in a controlled, multicentre, multinational study conducted in six headache centres located in Europe and Latin America. A total of 663 MOH subjects were enrolled and divided into two groups: the Comoestas group was monitored with an electronic diary associated with an alert system and a facilitated communication option, and the Classic group with a paper headache diary. Results We observed a significantly higher percentage of overuse-free subjects in the Comoestas group compared with the Classic group: 73.1 vs 64.1% (odds ratio 1.45, 95% confidence interval 1.07-2.09, p = 0.046). The Comoestas group performed better also regarding the number of days/month with intake of acute drugs and the level of disability [Migraine Disability Assessment Score: Comoestas group - 42.5 ± 53.6 (35.5-49.3) and Classic group - 27.5 ± 56.1 (20.6-34.3) ( p < 0.003)]. Conclusion The adoption of the electronic tool improved the outcome of patients suffering from MOH after withdrawal from overused drugs. Information and communication technology represents a valid aid for optimizing the management of chronic conditions at risk of worsening or of relapsing. Trial registration The trial was registered at ClinicalTrials.gov (no. NCT02435056).
AB - Background Medication-overuse headache (MOH) is a chronic disabling condition associated with a high rate of relapse. Methods We evaluated whether the adoption of electronic-assisted monitoring, advice and communication would improve the outcome over a follow-up of 6 months in a controlled, multicentre, multinational study conducted in six headache centres located in Europe and Latin America. A total of 663 MOH subjects were enrolled and divided into two groups: the Comoestas group was monitored with an electronic diary associated with an alert system and a facilitated communication option, and the Classic group with a paper headache diary. Results We observed a significantly higher percentage of overuse-free subjects in the Comoestas group compared with the Classic group: 73.1 vs 64.1% (odds ratio 1.45, 95% confidence interval 1.07-2.09, p = 0.046). The Comoestas group performed better also regarding the number of days/month with intake of acute drugs and the level of disability [Migraine Disability Assessment Score: Comoestas group - 42.5 ± 53.6 (35.5-49.3) and Classic group - 27.5 ± 56.1 (20.6-34.3) ( p < 0.003)]. Conclusion The adoption of the electronic tool improved the outcome of patients suffering from MOH after withdrawal from overused drugs. Information and communication technology represents a valid aid for optimizing the management of chronic conditions at risk of worsening or of relapsing. Trial registration The trial was registered at ClinicalTrials.gov (no. NCT02435056).
U2 - 10.1177/0333102416660549
DO - 10.1177/0333102416660549
M3 - Journal article
C2 - 27440251
VL - 37
SP - 1115
EP - 1125
JO - Cephalalgia
JF - Cephalalgia
SN - 0800-1952
IS - 12
ER -
ID: 193976044